Improving inhalation parameters through dry powder inhalers (DPIs) after an acute asthma exacerbation Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Dose delivery characteristics of two dry powder inhalers in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 291s Year: 2004
Comparison of two dry powder inhalers containing budesonide in the treatment of asthma in children Source: Eur Respir J 2002; 20: Suppl. 38, 500s Year: 2002
A novel NEXT DPI® dry powder inhaler and its use in asthmatic and COPD population Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Do dry powder inhalers (DPIs) have a ‘Goldilocks Zone’ of inhalation? In vitro lung deposition of Budesonide/Formoterol (BUD/FORM) DPI with different inhalation profiles Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017
Handling and patient preference of dry powder inhalers for asthma and COPD Source: Eur Respir J 2006; 28: Suppl. 50, 210s Year: 2006
Systemic activity of two different dry powder combinations of inhaled corticosteroids and long-acting β2-agonists in children with asthma assessed by knemometry Source: Annual Congress 2012 - Assessing and treating childhood asthma and allergy Year: 2012
Do asthma patients achieve effective dosing from dry powder inhalers (DPIs)? Source: Eur Respir J 2005; 26: Suppl. 49, 338s Year: 2005
Comparison of total and fine drug particle mass generated from two dry powder inhalers (DPIs) by 4-year old children with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 429s Year: 2002
The investigation of inhalation continuous duration for dry powder inhalers in asthmatic patients Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
One-year height growth in children with asthma treated with inhaled budesonide delivered from a new dry powder inhaler. Source: Annual Congress 2008 - Clinical aspects of asthma in school-aged children Year: 2008
Dry powder inhalers in asthma and COPD. Which factors determine the frequency of handling errors? Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology Year: 2007
Inspiratory profiles and consistency of behaviour regarding dose delivery characteristics of two dry powder inhalers in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 13s Year: 2004
Comparison of a formoterol multiple dose dry powder inhaler (MDPI) with a formoterol single dose dry powder inhaler (SDPI) in patients with moderate to severe asthma Source: Eur Respir J 2004; 24: Suppl. 48, 260s Year: 2004
Applicability of dry powder inhalers in children with CF Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016
Inhalation characteristics of asthmatic children (child), adults asthmatics (adult) and chronic obstructive pulmonary disease patients when they inhale through a spiromax dry powder inhaler (DPI) Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
The small airway inflammation of asthmatic patients who have used dry powder type inhaled steroid for moderate-long term evaluated by induced sputum and the efficacy of HFA-BDP (QVAR) inhalation Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005
Carbon footprint of severe asthma exacerbation management relative to Breezhaler dry powder inhaler Source: Virtual Congress 2021 – Environment and respiratory health Year: 2021
Computerized measurements of inhalation ability with a dry powder inhaler in patients with severe COPD Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more Year: 2020
Acceptability of two dry powder inhalers in 645 asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 338s Year: 2005